Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Impact of corticosteroids in fungal keratitis

Search Title by author or title

Session Details

Session Title: Cornea: Medical

Session Date/Time: Tuesday 10/10/2017 | 08:00-10:30

Paper Time: 08:36

Venue: Room 3.6

First Author: : K.Belkhadir MOROCCO

Co Author(s): :    Z. Bettich   I. Sabrane   M. El Ikhloufi   A. Amazouzi   R. Daoudi   O. Cherkaoui     

Abstract Details


Fungal keratitis are serious infections of the cornea, most often occurring in a fragile context. Corticosteroid therapy is contraindicated when a mycotic origin of the abscess is suspected. In our context, patients have easy access to corticosteroids and use them as auto-medication. The aim of our work was to analyze the specific complications of corticosteroids in case of fungal keratitis.


Ophtalmology A Unit at the Ibn Sina university Hospital in Rabat, Morocco.


This is a retrospective study carried out in the Ophtalmology A Unit at the Ibn Sina university Hospital in Rabat, Morocco. All patients admitted for fungal keratitis management were included between October 2014 and October 2016.


We collected 27 cases of fungal keratitis. Twelve patients used corticosteroid eye drops before hospitalization. These patients had larger abscesses with a mean major axis of 6 mm vs. 4 mm (p = 0.004). These abscesses were complicated with decemetocoelia in 8 cases vs. 3 cases (p = 0.022). During treatment, patients who received corticosteroids had more corneal perforations occurring in 9 cases vs 4 cases (p = 0.013) and posterior synechiae in 10 cases (37%) vs 5 cases (18.5%) (p = 0.009). This resulted in an increased length of hospital stay (22.7 days vs. 17.9 days. p = 0.046)


The use of corticosteroids in mycotic keratitis leads to more serious and wider lesions, providing more complications, in particular of corneal perforations and posterior synechiae.

Financial Disclosure:


Back to previous